Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea.
Leuk Res. 2012 Sep;36(9):1172-8. doi: 10.1016/j.leukres.2012.05.004. Epub 2012 Jun 2.
To understand the molecular mechanism(s) underlying bortezomib resistance, we sought to identify potential target genes that were differentially expressed in bortezomib-resistant leukemia cells versus parental controls. Microarray analysis revealed that the mRNA levels of Rad (Ras associated with diabetes) were higher in the bortezomib-resistant Jurkat (Jurkat-R) cells than in the parental control cells. The importance of Rad for bortezomib resistance was supported by three observations. First, Rad knockdown overcame bortezomib resistance and induced mitochondrial apoptosis via Noxa/Bcl-2 modulation. Second, Rad decreased cell death in response to bortezomib. Third, leukemia and lymphoma cell lines (K-562, Raji, IM-9 and Jurkat-R) with elevated Rad expression levels showed higher degrees of bortezomib resistance versus those (Sup-B15, JVM-2, U266 and Jurkat) with low Rad expression levels (r=0.48, P=0.0004). Thus, Rad over expression could be a molecular target to improve bortezomib sensitivity in human leukemia and lymphoma.
为了理解硼替佐米耐药的分子机制,我们试图鉴定在硼替佐米耐药白血病细胞与亲本对照中差异表达的潜在靶基因。微阵列分析显示,在硼替佐米耐药的 Jurkat(Jurkat-R)细胞中,Rad(与糖尿病相关的 Ras)的 mRNA 水平高于亲本对照细胞。Rad 对硼替佐米耐药的重要性得到了三个观察结果的支持。首先,Rad 敲低克服了硼替佐米耐药,并通过 Noxa/Bcl-2 调节诱导线粒体凋亡。其次,Rad 减少了对硼替佐米的细胞死亡。第三,具有高 Rad 表达水平的白血病和淋巴瘤细胞系(K-562、Raji、IM-9 和 Jurkat-R)与低 Rad 表达水平的细胞系(Sup-B15、JVM-2、U266 和 Jurkat)相比,表现出更高程度的硼替佐米耐药(r=0.48,P=0.0004)。因此,Rad 过表达可能成为提高人类白血病和淋巴瘤中硼替佐米敏感性的分子靶标。